Fourth COVID vaccine shot found to be highly effective

For our free coronavirus pandemic coverage, learn more here.

Jerusalem: A fourth dose of COVID-19 vaccine given to people over 60 in Israel made them three times more resistant to serious illness than thrice-vaccinated people in the same age group, Israel’s Health Ministry said.

The ministry also said on Sunday that the fourth dose, or second booster, made people over 60 twice as resistant to infection than those in the age group who received three shots of the vaccine.

Heart transplant patient Moshe Geva Rosso receives a fourth dose of the COVID vaccine in Ramat Gan, Israel. Credit:Getty Images

A preliminary study published by Israel’s Sheba medical centre last Monday found that the fourth shot increases antibodies to even higher levels than the third but “probably” not to the point that it could completely fend off the highly transmissible Omicron variant.

Israel began offering a fourth dose of the Pfizer/BioNtech vaccine to people over 60 earlier this month as Omicron swept the country.

The ministry on Sunday said the study it conducted with several major Israeli universities and the Sheba centre compared 400,000 people over 60 who received the second booster with 600,000 people in the age group who were given a third shot more than four months ago.

As elsewhere, Israel has seen COVID-19 cases spiral due to Omicron. But it has logged no deaths from the variant.

Pfizer chief executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.

In an interview with Israel’s N12 News, Bourla was asked whether he sees booster shots being administered every four to five months on a regular basis.

“This will not be a good scenario. What I’m hoping [is] that we will have a vaccine that you will have to do once a year,” Bourla said.

“Once a year – it is easier to convince people to do it. It is easier for people to remember.

“So from a public health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers Omicron and doesn’t forget the other variants and that could be a solution,” Bourla said.

Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March.

Citing three studies, the US Centres for Disease Control and Prevention (CDC) said on Friday that a third dose of an mRNA vaccine is key to fighting Omicron, providing 90 per cent protection against hospitalisation.

Reuters

Most Viewed in World

From our partners

Source: Read Full Article